Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis

Frontiers in Endocrinology

Volumn 6, Issue , 2015, Pages

  Moss, Mary E ^a,b   Jaffe, Iris Z ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aldosterone; atherosclerosis CAD; mineralocorticoid receptor antagonists; mineralocorticoid receptors; vascular inflammation

Indexed keywords

EID: 84962075546     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00153     Document Type: Review

References (55)

1. Brown NJ. Aldosterone and vascular inflammation. Hypertension (2008) 51(2):161–7.10.1161/HYPERTENSIONAHA.107.095489
2. Khan R Spagnoli V Tardif JC L’Allier PL. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Atherosclerosis (2015) 240(2):497–509.10.1016/j.atherosclerosis.2015.04.78325917947
3. Gomez-Sanchez E Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol (2014) 4(3):965–94.10.1002/cphy.c130044
4. McCurley A Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol (2012) 350(2):256–65.10.1016/j.mce.2011.06.01421723914
5. Meinel S Gekle M Grossmann C. Mineralocorticoid receptor signaling: crosstalk with membrane receptors and other modulators. Steroids (2014) 91:3–10.10.1016/j.steroids.2014.05.01724928729
6. Nagase M Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol (2013) 9(2):86–98.10.1038/nrneph.2012.28223296296
7. Pitt B Zannad F Remme WJ Cody R Castaigne A Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med (1999) 341(10):709–17.10.1056/NEJM19990902341100110471456
8. Volterrani M Iellamo F. Eplerenone in chronic heart failure with depressed systolic function. Int J Cardiol (2015).10.1016/j.ijcard.2015.05.12626044084
9. Milliez P Girerd X Plouin PF Blacher J Safar ME Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol (2005) 45(8):1243–8.10.1016/j.jacc.2005.01.01515837256
10. Ivanes F Susen S Mouquet F Pigny P Cuilleret F Sautiere K et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J (2012) 33(2):191–202.10.1093/eurheartj/ehr17621719456
11. de Rita O Hackam DG Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol (2012) 28(6):706–11.10.1016/j.cjca.2012.04.01422717248
12. Tikellis C Pickering RJ Tsorotes D Huet O Chin-Dusting J Cooper ME et al. Activation of the renin-angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. Hypertension (2012) 60(1):98–105.10.1161/HYPERTENSIONAHA.112.19176722647892
13. McGraw AP Bagley J Chen WS Galayda C Nickerson H Armani A et al. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc (2013) 2(1):e000018.10.1161/JAHA.112.00001823525413
14. Keidar S Hayek T Kaplan M Pavlotzky E Hamoud S Coleman R et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol (2003) 41(6):955–63.10.1097/00005344-200306000-0001912775976
15. Raz-Pasteur A Gamliel-Lazarovich A Coleman R Keidar S. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol (2012) 60(6):508–12.10.1097/FJC.0b013e31826f553523232789
16. Raz-Pasteur A Gamliel-Lazarovich A Gantman A Coleman R Keidar S. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice. J Renin Angiotensin Aldosterone Syst (2014) 15(3):228–35.10.1177/147032031246755823223089
17. Mohandas A Suboc TB Wang J Ying R Tarima S Dharmashankar K et al. Mineralocorticoid exposure and receptor activity modulate microvascular endothelial function in African Americans with and without hypertension. Vasc Med (2015).10.1177/1358863X1558475325978968
18. Leopold JA Dam A Maron BA Scribner AW Liao R Handy DE et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 13(2):189–97.10.1038/nm154517273168
19. Garg R Rao AD Baimas-George M Hurwitz S Foster C Shah RV et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes (2015) 64(1):236–42.10.2337/db14-067025125488
20. Heylen E Huang A Sun D Kaley G. Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J Cardiovasc Pharmacol (2009) 54(6):535–42.10.1097/FJC.0b013e3181bfb00d19770672
21. Schafer N Lohmann C Winnik S van Tits LJ Miranda MX Vergopoulos A et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J (2013) 34(45):3515–24.10.1093/eurheartj/eht09523594590
22. Barrett Mueller K Bender SB Hong K Yang Y Aronovitz M Jaisser F et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension (2015).10.1161/HYPERTENSIONAHA.115.0617226351033
23. Rickard AJ Morgan J Chrissobolis S Miller AA Sobey CG Young MJ. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension (2014) 63(5):1033–40.10.1161/HYPERTENSIONAHA.113.0180324566081
24. Adel H Taye A Khalifa MM. Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol (2014) 387(12):1187–97.10.1007/s00210-014-1048-325238812
25. McClain JL Dorrance AM. Temporary mineralocorticoid receptor antagonism during the development of hypertension improves cerebral artery dilation. Exp Biol Med (Maywood) (2014) 239(5):619–27.10.1177/153537021452258624625441
26. Tzamou V Vyssoulis G Karpanou E Kyvelou SM Gialernios T Stefanadis C. Aldosterone levels and inflammatory stimulation in essential hypertensive patients. J Hum Hypertens (2013) 27(9):535–8.10.1038/jhh.2013.1323486351
27. Cooper JN Tepper P Barinas-Mitchell E Woodard GA Sutton-Tyrrell K. Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. Clin Exp Hypertens (2012) 34(1):63–70.10.3109/10641963.2011.61820022007645
28. Zhang L Hao JB Ren LS Ding JL Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest (2014) 94(8):839–50.10.1038/labinvest.2014.6924862968
29. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol (2009) 1(6):a001651.10.1101/cshperspect.a00165120457564
30. Leroy V De Seigneux S Agassiz V Hasler U Rafestin-Oblin ME Vinciguerra M et al. Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol (2009) 20(1):131–44.10.1681/ASN.200802023218987305
31. Sanz-Rosa D Cediel E De las HN Miana M Balfagon G Lahera V et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens (2005) 23(6):1167–72.10.1097/01.hjh.0000170379.08214.5a15894892
32. Zhu CJ Wang QQ Zhou JL Liu HZ Hua F Yang HZ et al. The mineralocorticoid receptor-p38MAPK-NFkappaB or ERK-Sp1 signal pathways mediate aldosterone-stimulated inflammatory and profibrotic responses in rat vascular smooth muscle cells. Acta Pharmacol Sin (2012) 33(7):873–8.10.1038/aps.2012.3622659623
33. Caprio M Newfell BG la SA Baur W Fabbri A Rosano G et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res (2008) 102(11):1359–67.10.1161/CIRCRESAHA.108.17423518467630
34. Barrett Mueller K Lu Q Mohammad NN Luu V McCurley A Williams GH et al. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology (2014) 155(11):4461–72.10.1210/en.2014-127025051445
35. Terada Y Ueda S Hamada K Shimamura Y Ogata K Inoue K et al. Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. Clin Exp Nephrol (2012) 16(1):81–8.10.1007/s10157-011-0498-x22042038
36. Kirsch T Beese M Wyss K Klinge U Haller H Haubitz M et al. Aldosterone modulates endothelial permeability and endothelial nitric oxide synthase activity by rearrangement of the actin cytoskeleton. Hypertension (2013) 61(2):501–8.10.1161/HYPERTENSIONAHA.111.19683223213194
37. Bene NC Alcaide P Wortis HH Jaffe IZ. Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids (2014) 91:38–45.10.1016/j.steroids.2014.04.00524769248
38. Suzuki J Iwai M Mogi M Oshita A Yoshii T Higaki J et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol (2006) 26(4):917–21.10.1161/01.ATV.0000204635.75748.0f16424347
39. Usher MG Duan SZ Ivaschenko CY Frieler RA Berger S Schutz G et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest (2010) 120(9):3350–64.10.1172/JCI4108020697155
40. Ji WJ Ma YQ Zhou X Zhang YD Lu RY Guo ZZ et al. Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments. PLoS One (2013) 8(11):e81090.10.1371/journal.pone.008109024260540
41. Besedovsky L Linz B Born J Lange T. Mineralocorticoid receptor signaling reduces numbers of circulating human naive T cells and increases their CD62L, CCR7, and CXCR4 expression. Eur J Immunol (2014) 44(6):1759–69.10.1002/eji.20134426524595810
42. Amador CA Barrientos V Pena J Herrada AA Gonzalez M Valdes S et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension (2014) 63(4):797–803.10.1161/HYPERTENSIONAHA.113.0288324420551
43. Herrada AA Contreras FJ Marini NP Amador CA Gonzalez PA Cortes CM et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol (2010) 184(1):191–202.10.4049/jimmunol.080288619949098
44. Gilet A Zou F Boumenir M Frippiat JP Thornton SN Lacolley P et al. Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways. Exp Cell Res (2015) 331(1):152–63.10.1016/j.yexcr.2014.11.00425449697
45. Deuchar GA McLean D Hadoke PW Brownstein DG Webb DJ Mullins JJ et al. 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology (2011) 152(1):236–46.10.1210/en.2010-092521106873
46. Bodary PF Sambaziotis C Wickenheiser KJ Rajagopalan S Pitt B Eitzman DT. Aldosterone promotes thrombosis formation after arterial injury in mice. Arterioscler Thromb Vasc Biol (2006) 26(1):233.10.1161/01.ATV.0000195782.07637.44
47. Stankiewicz A Gromotowicz A Szemraj J Wojewodzka-Zelezniakowicz M Skrzypkowski P Chabielska E. Acute aldosterone infusion enhances thrombosis development in normotensive rats. Thromb Haemost (2007) 98(3):697–9.10.1160/TH07-03-0237
48. Zakrzeska A Gromotowicz-Poplawska A Szemraj J Szoka P Kisiel W Purta T et al. Eplerenone reduces arterial thrombosis in diabetic rats. J Renin Angiotensin Aldosterone Syst (2014).10.1177/147032031351503725031293
49. Gromotowicz A Szemraj J Stankiewicz A Zakrzeska A Mantur M Jaroszewicz E et al. Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst (2011) 12(4):430–9.10.1177/147032031039740521421657
50. Schafer A Vogt C Fraccarollo D Widder J Flierl U Hildemann SK et al. Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J Physiol Pharmacol (2010) 61(1):45–52.20228414
51. Schafer A Fraccarollo D Hildemann S Christ M Eigenthaler M Kobsar A et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost (2003) 89(6):1024–30.12783115
52. Brown NJ Nakamura S Ma L Nakamura I Donnert E Freeman M et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int (2000) 58(3):1219–27.10.1046/j.1523-1755.2000.00277.x10972684
53. Ducros E Berthaut A Mirshahi SS Faussat AM Soria J Agarwal MK et al. Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. Biochem Biophys Res Commun (2008) 373(2):192–6.10.1016/j.bbrc.2008.05.18518555797
54. Lagrange J Li Z Fassot C Bourhim M Louis H Nguyen Dinh CA et al. Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. FASEB J (2014) 28(5):2062–72.10.1096/fj.13-23818824451386
55. Mosnier LO Zlokovic BV Griffin JH. The cytoprotective protein C pathway. Blood (2007) 109(8):3161–72.10.1182/blood-2006-09-00300417110453